Corcept's Lifyorli Launch Drives Revenue Growth, Masks Rising Expenses
Event summary
- Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, a 3.4% increase year-over-year.
- Operating expenses rose significantly to $214.5 million in Q1 2026, compared to $153.8 million in Q1 2025, driven by Lifyorli launch preparation and Cushing’s syndrome growth initiatives.
- The company expects to return to profitability in Q2 2026 following a net loss per share of $0.30 in Q1 2026.
- Lifyorli, approved for platinum-resistant ovarian cancer, was added to NCCN Guidelines in April 2026, leading to vigorous uptake.
- Corcept increased its full-year 2026 revenue guidance to $950 - $1,050 million.
The big picture
Corcept's rapid revenue growth is largely attributable to the successful FDA approval and subsequent NCCN inclusion of Lifyorli. However, the company's significant increase in operating expenses, driven by launch preparations and ongoing development programs, is masking a loss in the short term. The company's ability to manage these expenses and demonstrate continued clinical success will be crucial for long-term value creation.
What we're watching
- Expense Management
- The substantial increase in operating expenses warrants close monitoring to ensure profitability targets are met as Lifyorli sales ramp up and other development programs advance.
- Clinical Trial Data
- The upcoming results from the BELLA and MONARCH trials will be critical in determining the long-term commercial potential of Lifyorli and miricorilant, respectively.
- Regulatory Landscape
- The FDA’s path forward for relacorilant in Cushing’s syndrome remains uncertain, and the outcome of this review will significantly impact Corcept’s future revenue stream.
